Unknown

Dataset Information

0

Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer.


ABSTRACT: BET bromodomain inhibitors (BETi) are promising therapeutic regimens for epithelial ovarian cancer (EOC). However, early-stage clinical trials indicate that drug tolerance may limit their anti-tumor efficacy. Here, we show that JQ1-refractory EOC cells acquire reversible resistance to BET inhibition and remain dependent on BRD4 function. The insensitivity is driven by a unique non-genetic mechanism that involves clonal selection for a pre-existing cell subpopulation with ample acetylated histones and sufficient nuclear phase-separated BRD4 droplets to counteract BETi antagonism. A vertical combination approach by co-blocking BET proteins and downstream Aurora kinases proves to achieve more complete responses than single inhibitors. Collectively, our study implicates epigenetic heterogeneity in therapeutic resistance to chromatin-targeted agents and proposes a rational strategy to address this anticipated clinical dilemma.

SUBMITTER: Sun Y 

PROVIDER: S-EPMC8263684 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2015-09-08 | E-GEOD-63782 | biostudies-arrayexpress
2015-09-08 | GSE63782 | GEO
| S-EPMC5745042 | biostudies-literature
| S-EPMC4921058 | biostudies-literature
2016-07-21 | E-GEOD-82329 | biostudies-arrayexpress
| S-EPMC6405739 | biostudies-literature
| S-EPMC4729770 | biostudies-literature
| S-EPMC4972668 | biostudies-literature
| S-EPMC4108909 | biostudies-literature
| PRJNA269063 | ENA